Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
NASHVILLE, Tenn., Nov. 1, 2024 /PRNewswire/ -- As previously announced, on September 4, 2024, APX Acquisition Corp. I (NASDAQ: APXI) (the "Company"), received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") indicating that since the Company's aggregate market value of its outstanding warrants was less than $1 million, the Company was no longer in compliance with the Nasdaq Global Market continued listing criteria set forth in Listing Rule 5452(b)(C) (the "Rule"), which requires the Company to maintain an aggregate market value of its outstanding warrants of at least $1 million (the "Notice"). The Company subsequently submitted a plan to regai
NASHVILLE, Tenn., June 5, 2024 /PRNewswire/ -- APX Acquisition Corp. I (NASDAQ: APXI) ("Company"), a publicly traded special purpose acquisition company, today announced that it received a deficiency letter (the "Letter") on May 30, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"). The Letter notified the Company that since the Company had not yet filed its Annual Report on Form 10-K for the year ended December 31, 2023 (the "Form 10-K") and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the "Form 10-Q"), the Company does not comply with Nasdaq's Listing Rule 5250(c)(1) relating to the Company's obligation to file periodic financi
NASHVILLE, Tenn., March 26, 2024 /PRNewswire/ -- APx Acquisition Corp. I (NASDAQ:APXI) ("APx"), a publicly traded special purpose acquisition company, OmnigenicsAI Corp ("OmnigenicsAI"), a precision medicine company incubated by Bioceres Group PLC, and MultiplAI Health Ltd ("MultiplAI"), a UK-based AI-enabled preventive medicine company, have entered into a definitive Business Combination Agreement ("BCA") that, upon closing, would result in OmnigenicsAI becoming a publicly listed company. The transaction is expected to close mid-year, subject to the approval of APx's shareholders and other customary closing conditions and, upon closing, OmnigenicsAI's shares are expected to be listed on Nas
4 - APx Acquisition Corp. I (0001868573) (Issuer)
4 - APx Acquisition Corp. I (0001868573) (Issuer)
4 - APx Acquisition Corp. I (0001868573) (Issuer)
SCHEDULE 13G - APx Acquisition Corp. I (0001868573) (Subject)
SCHEDULE 13G/A - APx Acquisition Corp. I (0001868573) (Subject)
8-K - APx Acquisition Corp. I (0001868573) (Filer)
SC 13G - APx Acquisition Corp. I (0001868573) (Subject)
SC 13G - APx Acquisition Corp. I (0001868573) (Subject)
SC 13G/A - APx Acquisition Corp. I (0001868573) (Subject)